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ABSTRACT 
Objective: To demonstrates the ability of P. macrocarpa leaf extract to reduce inflammation of the distal colon in DSS/AOM-induced mice.  
Methods: In vivo experimental research using Balb/c mice induced by 0.2 ml azoxymethane (AOM) 0.1% once and 1% dextran sodium sulphate 
(DSS) for one week; additionally, ethanol extract of P. macrocarpa leaves, 25 mg and 50 mg, and 0.84 mg acetosal were given orally. The mice were 
sacrificed after 20 w. Histopathological examination (hematoxylin-eosin staining) was conducted by counting the average number of goblet cells per 
crypt, inflammatory focus and angiogenesis.  
Results: Ethanol extract of P. macrocarpa leaves was able to prevent the decrease in the number of goblet cells (p<0.05). However, the 
administration of ethanol P. macrocarpa leaf extract could not reduce focal inflammation and angiogenesis in inflammation of the distal colon.  
Conclusion: Ethanol extract of the Mahkota Dewa leaves is able to prevent inflammation of the distal colon by preventing the decrease in the 
number of goblet cells. 
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UC is chronic gastrointestinal inflammation that occurs in the 
epithelial lining of the large intestine, which causes stomach pain, 
diarrhea and gastrointestinal bleeding [1]. The global UC incidence 
is 1.2–20.3 per 100,000 people annually, with a prevalence of 7.6 to 
246 per 100,000 people. The incidence and prevalence of 
Inflammatory Bowel Disease (IBD) is high in European and 
American populations, whereas in Asian populations, the number of 
reported cases is low [2]. Patients with UC have a 50% chance of 
recurrence and 20–30% require colectomy for treatment [3]. 
UC is a disease caused by immunological mechanisms that occur in 
people with a genetic predisposition due to an immune system that 
cannot normally respond to intraluminal antigens; antigens that 
cause this immunological mechanism are commensal bacteria in the 
digestive tract [4]. Histopathological examination shows a change in 
cryptic architecture (shortening or branching crypts), 
lymphoplasmasitosis basalis and Paneth cell metaplasia [5]. 
Currently, the choice of UC management depends on the degree of 
the disease, distribution, causes, frequency of recurrence, 
extraintestinal manifestations, previous treatment and side effects of 
the drugs prescribed. The goal of UC management is to provide an 
improvement in conditions with minimal consumption of steroids 
while preventing disease complications. The first-line drug given for 
mild-to-moderate UC is 5-ASA; this drug has been studied by many 
researchers and shows positive effects in dealing with UC. 
Unfortunately, 5-ASA can cause a number of side effects, such as 
diarrhea, nausea, vomiting, headaches and fever, so special attention 
is required in the use of 5-ASA [6, 7]. 
Considering these serious health problems, there needs to be an 
effective, efficient treatment with minimal side effects. Indonesian 
people have long used many natural substances as medicines; one of 
these is the Mahkota Dewa (Phaleria macrocarpa) leaf. Numerous 
studies have shown the pharmacological effects of the extract of the 
P. macrocarpa, such as anti-cancer, antioxidant, antibacterial and 
anti-inflammatory effects. One of the active ingredients of the P. 
macrocarpa extract is phalerin, which works by suppressing the 
expression of COX2 which causes decreased synthesis of 
prostaglandin so that the inflammatory reaction is reduced [8]. 
MATERIALS AND METHODS 
Sample size 
The number of samples used in this study was calculated using the 
Federer formula (t-1) (n-1) ≥ 15. The number of groups in this study 
was 5 groups, so the number of replications in each group was:  
 (5-1) (n-1) ≥ 15 heads 
 (n-1)/4 15/4 
 (n-1) ≥ 3175 
 n ≥ 4.75 
Based on the calculation of the formula above, five mice were 
obtained for each group; in total, 25 Balb/c mice, which were 
randomly divided into five groups, were used. 
Material 
Dextran sodium sulfate (DSS) with a molecular weight of 36,000–
50,000 was obtained from Regent Science Industry Limited (RSC), 
Hong Kong. The ethanol extract of P. macrocarpa leaves was 
obtained from the Biopharmaca IPB Study Center, Bogor, Indonesia. 
Experiment design 
In vivo experimental research using Balb/c mice divided into five 
groups. Each group consists of 5 mice:  
1. The normal group (N) consisted of mice that were not given any 
treatment. 
2. The negative group (K-) consisted of mice given 0.2 ml AOM 
0.1% w/v ip once for seven days and then given a 1% w/v DSS 
solution through drinking water every day for seven days ad libitum. 
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3. Positive group (K+) consisted of mice given 0.2 ml AOM 0.1% 
w/v ip once for seven days and then given an oral suspension of 
acetosal 0.4% w/v in the amount of 0.21 ml (equivalent to 0.84 mg 
of acetosal) and a 1% w/v DSS solution with drinking water every 
day for seven days ad libitum. 
4. High dose group (DT) consisted of mice given 0.2 ml AOM 0.1% 
w/v ip once for seven days and then given an extract of 25% w/v P. 
macrocarpa orally in the amount of 0.2 ml (equivalent to 50 mg 
extract) and 1% DSS w/v solution with drinking water every day for 
seven days ad libitum. 
5. The low dose group (DR) consisted of mice given 0.2 ml AOM 
0.1% w/v ip once for seven days, and then given 12.5% w/v P. 
macrocarpa leaf extract orally in the amount of 0.2 ml (equivalent to 
25 mg extract) and a 1% DS w/v solution with drinking water every 
day for seven days ad libitum. 
Mice were sacrificed after 20 w of being given treatment according 
to their group. Distal colonic tissue was then stained with 
hematoxylin-eosin for histopathological observation. 
Histopathological examination 
Histopathological observations were made at the Pathological Anatomy 
Laboratory FKUI, Jakarta, Indonesia. Observations focused on calculating 
the number of goblet cells per crypt, the focus of inflammation and 
angiogenesis in six predetermined fields. Observations were made in a 
double-blind manner. Observations were made at 400-times 
magnification and then analyzed using ImageJ software (NHI). 
Ethical approval 
This study passed the ethical review from the Faculty of Medicine 
University of Indonesia Health Research Ethics Committee with 
letter number 0891/UN2. FI/ETIK/2018. 
Statistical analysis 
Statistical analysis was performed using the One-Way ANOVA test, 
followed by Tukey's Post Hoc test for goblet cell variables and 
inflammatory focus. Angiogenesis variables were analyzed using the 
Kruskal-Wallis test because the data distribution was not normal. 
RESULTS 
Effect of administration of P. macrocarpa leaf extract on the 
number of goblet cells 
Goblet cells play a protective function in the mucosal lining of the 
colon by secreting mucosa [9–11]. Damage to the mucous layer 
causes an increase in permeability to bacteria and toxins that can 
damage epithelial cells and cause systemic inflammation, such as UC 
[12]. In UC, there is a depletion of goblet cells due to inflammation 
processes. This is related to a decrease in glycosylation of mucin 
accompanied by the absence of the MUC2 and MUC3 genes in goblet 
cells [13]. Goblet cell depletion in UC is also associated with 
impaired induction of Hath1 and KLF4 differentiation factors during 
inflammation [14]. The effect of P. macrocarpa extract on observed 
goblet cell counts with hematoxylin-eosin staining using 400-times 
magnification is shown in fig. 1. 
 
 
Fig. 1: Effect of administration mahkota dewa extract to the number of goblet cells: (A) Normal group, (B) DSS/AOM+Aspirin 0.86 mg, (C) 
DSS/AOM+50 mg extract, (D) DSS/AOM+Extract 25 mg and (E) DSS/AOM 
 
The administration of P. macrocarpa leaf extract was able to prevent a 
significant decrease in the number of goblet cells (p<0.05) (fig. 2). The 
results of this study are supported by a number of other studies. A 
study by Suprapti et al. examined the effect of the P. macrocarpa leaf 
extract on colon inflammation in mice. From this study, it was 
concluded that the P. macrocarpa leaf extract can reduce colonic tissue 
damage and prevent an increase in the expression of COX-2, NOS and 
β-catenin [15]. A study by Maharani et al. showed that the P. 
macrocarpa leaf extract with a dose of 100 mg, 200 mg, and 300 mg 
can inhibit a decrease in the number of goblet cells in the colon [16]. 
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 Effect of administration of P. macrocarpa leaf extract 
Fig. 2: Administration of Dewa Dewa leaf extract to normal 
The administration of DSS to the colon was able to increase the 
number of angiogenesis. In this study, the administration of the 
 
Fig. 3: Effect of administration of dewa dewa 
DSS/AOM+50 mg extract, (DR) DSS/AOM
Effect of administration of P. macrocarpa 
amount of inflammatory focus 
The focus of active inflammation is defined as cryptic damage due to 
neutrophil infiltration. The discovery of neutrophil infiltration in 
crypts and cryptic abscesses indicates an inflammatory focus. 
 
Fig. 4: Effect of administration of dewa dewa 
(DT) DSS/AOM
Kusmardi et al. 
Int J App Pharm, Vol 12, 
on the amount of angiogenesis 
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(DR) DSS/AOM+25 mg extract and (K-) DSS/AOM 
 
P. 
macrocarpa leaf extract did not reduce the amount of angiogenesis 
in the DSS/AOM-induced distal colitis (p = 0.895).
leaf extract to the number of angiogenesis (KN) normal group, (K
+25 mg extract and (K-) DSS/AOM
 
leaf extract on the Research by Osmond et al. showed that the focus of infla
leads to clinical diagnosis in UC
inflammation is characterized by the presence of neutrophils in the 
stool, whereas the severity of the 
neutrophil infiltration [19]. 
leaf extract to the number of focal inflammatory (KN) normal group, (K+) Aspirin 0.86 mg, 
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In this study, the administration of P. macrocarpa leaf extract did not 
show a reduction in the amount of inflammation in focus. The 
amount of inflammatory focus in the control group did not differ 
significantly with the group given the extract (p = 0.082) (fig. 4). 
DISCUSSION 
Phaleria macrocarpa is a tropical plant of the Thymelaceae family that 
commonly grows in Papua, Indonesia. Extracts of P. macrocarpa leaves 
are used for a number of pharmacological activities because of its anti-
tumor, anti-inflammatory and anti-fungal effects. Anti-inflammatory 
activity of P. macrocarpa are due to its contents, including tannins, 
terpenoids, saponins, flavonoids and phenols [8]. The aim of this study is 
to determine the histopathological effect of distal colon inflammation by 
inhibition of the ethanol extract of P. macrocarpa leaves.  
Goblet cells play a protective function in the mucosal lining of the 
colon by secreting mucosa [9–11]. Damage to the mucous layer 
causes increased permeability to bacteria and toxins that can 
damage epithelial cells and cause systemic inflammation, such as UC 
[12]. In UC, a depletion of the number of goblet cells occurs due to 
inflammation processes [13]. The results of this study show that 
there were significant differences in the number of distal colonic 
goblet cells between the groups given the extract of the P. 
macrocarpa leaves and the group that was only given AOM/DSS 
(p<0.05). Giving 25 mg and 50 mg dosages of P. macrocarpa leaf 
extract can prevent a decrease in the number of goblet cells after the 
inflammation process occurs; there is a significant difference 
between the 25 mg and 50 mg doses. In addition, high-dose (50 mg) 
P. macrocarpa leaf extract shows the same anti-inflammation effect 
(inhibitory decrease in the number of goblet cells) as acetosal. 
The results of this study are supported by a number of other studies. 
The study by Suprapti et al. examined the effect of the extract of P. 
macrocarpa leaf on colon inflammation in mice. From these studies, 
it was concluded that the extract of the P. macrocarpa leaf can 
reduce colonic tissue damage, as well as prevents an increase in 
COX-2, NOS and β-catenin expression [20]. Studies by Maharani et al. 
showed that 300 mg can inhibit a decrease in the number of goblet 
cells in the colon [16]. 
The increased amount of foci of inflammation in UC is caused by the 
role of neutrophils, which are the first immune cells that respond 
during the inflammation process. Uncontrolled activation of 
neutrophils with UC causes damage to the colonic epithelial tissue 
and allows infiltration into the crypts [21]. Showed the anti-
inflammatory effect of P. macrocarpa leaf extract by suppressing the 
amount of inflammatory focus in DSS-induced UC [16]. 
In this study, the administration of P. macrocarpa leaf extract did not 
show a significant difference (p>0.05). The amount of inflammatory 
focus in the control group did not differ significantly from the group 
given extract. In addition, the amount of inflammatory focus in the 
group that was given the highest dose of P. macrocarpa leaf extract 
showed the highest number of inflammatory focus. Differences in 
results from previous studies may be due to the longer induction 
period of this trial (20 w), which lead to apoptosis or carcinogenesis. 
In UC, continuous ulceration is followed by tissue regeneration. This 
increases the need for oxygen and nutrient supply to the colon 
tissue. Under physiological conditions, the process of angiogenesis 
occurs due to a balance between pro-and anti-angiogenic factors; 
but with UC, the process of angiogenesis becomes uncontrollable 
due to chronic inflammation, or what is referred to as ‘immune-
driven angiogenesis’ [22–25]. Administration of DSS does not 
increase the number of blood vessels in the distal colonic tissue. In 
addition, administration of acetosal or extracts of the P. macrocarpa 
leaf did not show a decrease in the number of angiogenesis. 
The ethanol extract of the P. macrocarpa leaves is able to prevent the 
inflammation process in the distal intestine by preventing a decrease in 
the number of goblet cells. However, P. macrocarpa leaf extract cannot 
reduce the amount of angiogenesis or inflammatory focus. 
CONCLUSION 
The ethanol extract of the Mahkota Dewa leaves (P. macrocarpa) is 
able to prevent the inflammatory process in the distal intestine by 
preventing a decrease in the number of goblet cells, but it cannot 
reduce the amount of angiogenesis and inflammatory focus. 
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